Atherothrombosis in von willebrand disease: An analysis of the literature and implications for clinical management

Seminars in Thrombosis and Hemostasis

Volumn 38, Issue 2, 2012, Pages 185-199

  Franchini, Massimo ^a   Coppola, Antonio ^b  

^a CARLO POMA HOSPITAL   (Italy)

^b FEDERICO II UNIVERSITY HOSPITAL   (Italy)

Author keywords

acute coronary syndrome; arterial thrombosis; atherosclerosis; cardiovascular disease; percutaneous coronary intervention; Von Willebrand disease; Von Willebrand factor

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; C REACTIVE PROTEIN; CANGRELOR; CLOPIDOGREL; DESMOPRESSIN; EPTIFIBATIDE; FIBRINOGEN; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HEMOGLOBIN; HEPARIN; HIRULOG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; PRASUGREL; THIENOPYRIDINE DERIVATIVE; TICAGRELOR; TICLOPIDINE; TIROFIBAN; VON WILLEBRAND FACTOR;

ACUTE CORONARY SYNDROME; ANGINA PECTORIS; ANTICOAGULANT THERAPY; ARTERIAL WALL THICKNESS; ARTERY CALCIFICATION; ARTERY THROMBOSIS; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; ATHEROTHROMBOSIS; BARE METAL STENT; BLEEDING; BLOOD CLOTTING FACTOR DEFICIENCY; CARDIOVASCULAR RISK; CELL MIGRATION; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM BLEEDING; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR ACCIDENT; CIGARETTE SMOKING; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; CORONARY STENT; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; DYSLIPIDEMIA; FIBRINOLYTIC THERAPY; HEART CATHETERIZATION; HEMOGLOBIN BLOOD LEVEL; HEMOPHILIA; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LOADING DRUG DOSE; LOW DRUG DOSE; NEUTROPHIL CHEMOTAXIS; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; NONHUMAN; PHYSICAL ACTIVITY; PRIMARY PREVENTION; PRIORITY JOURNAL; RECURRENT DISEASE; SMOOTH MUSCLE FIBER; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS; VENOUS THROMBOEMBOLISM; VON WILLEBRAND DISEASE; VON WILLEBRAND FACTOR DEFICIENCY;

ADULT; AGED; ASPIRIN; ATHEROSCLEROSIS; CARDIAC SURGICAL PROCEDURES; CORONARY ARTERY DISEASE; HEMOPHILIA A; HUMANS; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; THROMBOSIS; VON WILLEBRAND DISEASES; VON WILLEBRAND FACTOR;

EID: 84858134785     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0032-1301416     Document Type: Article

References (101)

1. Franchini M. Thrombotic complications in patients with hereditary bleeding disorders. Thromb Haemost: 2004; 92 2 298 304 (Pubitemid 39172310)
2. Girolami A, Ruzzon E, Fabris F, Varvarikis C, Sartori R, Girolami B. Myocardial infarction and other arterial occlusions in hemophilia A patients. A cardiological evaluation of all 42 cases reported in the literature. Acta Haematol: 2006; 116 2 120 125 (Pubitemid 44252768)
3. Girolami A, Tezza F, Scapin M, Vettore S, Casonato A. Arterial and venous thrombosis in patients with von Willebrand's disease: a critical review of the literature. J Thromb Thrombolysis: 2006; 21 2 175 178
4. Tuinenburg A, Mauser-Bunschoten EP, Verhaar MC, Biesma DH, Schutgens REG. Cardiovascular disease in patients with hemophilia. J Thromb Haemost: 2009; 7 2 247 254
5. Mannucci PM, Schutgens REG, Santagostino E, Mauser-Bunschoten EP. How I treat age-related morbidities in elderly persons with hemophilia. Blood: 2009; 114 26 5256 5263
6. Biere-Rafi S, Zwiers M, Peters M., et al. The effect of haemophilia and von Willebrand disease on arterial thrombosis: a systematic review. Neth J Med: 2010; 68 5 207 214
7. Coppola A, Tagliaferri A, Franchini M. The management of cardiovascular diseases in patients with hemophilia. Semin Thromb Hemost: 2010; 36 1 91 102
8. Schutgens REG, Tuinenburg A, Roosendaal G, Guyomi SH, Mauser-Bunschoten EP. Treatment of ischaemic heart disease in haemophilia patients: an institutional guideline. Haemophilia: 2009; 15 4 952 958
9. Sadler JE, Budde U, Eikenboom JC., et al. Working Party on von Willebrand Disease Classification. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost: 2006; 4 10 2103 2114 (Pubitemid 44403432)
10. Schneppenheim R, Budde U. von Willebrand factor: the complex molecular genetics of a multidomain and multifunctional protein. J Thromb Haemost: 2011; 9 Suppl 1 209 215
11. Mayadas T, Wagner DD, Simpson PJ. von Willebrand factor biosynthesis and partitioning between constitutive and regulated pathways of secretion after thrombin stimulation. Blood: 1989; 73 3 706 711 (Pubitemid 19069173)
12. Dong JF, Moake JL, Nolasco L., et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood: 2002; 100 12 4033 4039 (Pubitemid 35396870)
13. Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood: 1987; 69 2 454 459 (Pubitemid 17022013)
14. Federici AB. Diagnosis of inherited von Willebrand disease: a clinical perspective. Semin Thromb Hemost: 2006; 32 6 555 565 (Pubitemid 44453017)
15. Franchini M, Mannucci PM. Von Willebrand factor: another janus-faced hemostasis protein. Semin Thromb Hemost: 2008; 34 7 663 669
16. van Schie MC, van Loon JE, de Maat MP, Leebeek FW. Genetic determinants of von Willebrand factor levels and activity in relation to the risk of cardiovascular disease: a review. J Thromb Haemost: 2011; 9 5 899 908
17. Ruggeri ZM. Von Willebrand factor. Curr Opin Hematol: 2003; 10 2 142 149 (Pubitemid 36207970)
18. Goto S, Ikeda Y, Saldvar E, Ruggeri ZM. Distinct mechanisms of platelet aggregation as a consequence of different shearing flow conditions. J Clin Invest: 1998; 101 2 479 486 (Pubitemid 28067346)
19. Goto S, Sakai H, Goto M., et al. Enhanced shear-induced platelet aggregation in acute myocardial infarction. Circulation: 1999; 99 5 608 613 (Pubitemid 29077358)
20. Folsom AR, Wu KK, Rosamond WD, Sharrett AR, Chambless LE. Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation: 1997; 96 4 1102 1108 (Pubitemid 27344210)
21. Smith FB, Lee AJ, Fowkes FG, Price JF, Rumley A, Lowe GD. Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study. Arterioscler Thromb Vasc Biol: 1997; 17 11 3321 3325 (Pubitemid 28016094)
22. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC.; European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med: 1995; 332 10 635 641
23. Jager A, van Hinsbergh VW, Kostense PJ., et al. von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the Hoorn Study. Arterioscler Thromb Vasc Biol: 1999; 19 12 3071 3078 (Pubitemid 30029838)
24. Whincup PH, Danesh J, Walker M., et al. von Willebrand factor and coronary heart disease: prospective study and meta-analysis. Eur Heart J: 2002; 23 22 1764 1770 (Pubitemid 35334269)
25. Morange PE, Simon C, Alessi MC., et al. PRIME Study Group. Endothelial cell markers and the risk of coronary heart disease: the Prospective Epidemiological Study of Myocardial Infarction (PRIME) study. Circulation: 2004; 109 11 1343 1348 (Pubitemid 38387818)
26. van der Meer IM, Brouwers GJ, Bulk S., et al. Genetic variability of von Willebrand factor and risk of coronary heart disease: the Rotterdam Study. Br J Haematol: 2004; 124 3 343 347 (Pubitemid 38167985)
27. Folsom AR, Rosamond WD, Shahar E., et al. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Prospective study of markers of hemostatic function with risk of ischemic stroke. Circulation: 1999; 100 7 736 742 (Pubitemid 29383644)
28. Wieberdink RG, van Schie MC, Koudstaal PJ., et al. High von Willebrand factor levels increase the risk of stroke: the Rotterdam study. Stroke: 2010; 41 10 2151 2156
29. Wu O, Bayoumi N, Vickers MA, Clark P. ABO(H) blood groups and vascular disease: a systematic review and meta-analysis. J Thromb Haemost: 2008; 6 1 62 69
30. Miura M, Kaikita K, Matsukawa M., et al. Prognostic value of plasma von Willebrand factor-cleaving protease (ADAMTS13) antigen levels in patients with coronary artery disease. Thromb Haemost: 2010; 103 3 623 629
31. Bongers TN, de Bruijne EL, Dippel DW., et al. Lower levels of ADAMTS13 are associated with cardiovascular disease in young patients. Atherosclerosis: 2009; 207 1 250 254
32. van Schie MC, de Maat MP, Isaacs A., et al. Variation in the von Willebrand factor gene is associated with von Willebrand factor levels and with the risk for cardiovascular disease. Blood: 2011; 117 4 1393 1399
33. Mannucci PM. Platelet/von Willebrand factor inhibitors to the rescue of ischemic stroke. Arterioscler Thromb Vasc Biol: 2010; 30 10 1882 1884
34. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature: 2000; 407 6801 258 264
35. Major CD, Santulli RJ, Derian CK, Andrade-Gordon P. Extracellular mediators in atherosclerosis and thrombosis: lessons from thrombin receptor knockout mice. Arterioscler Thromb Vasc Biol: 2003; 23 6 931 939 (Pubitemid 36713544)
36. Coughlin SR, Camerer E. PARticipation in inflammation. J Clin Invest: 2003; 111 1 25 27 (Pubitemid 36134843)
37. Fuster V, Fass DN, Kaye MP, Josa M, Zinsmeister AR, Bowie EJ. Arteriosclerosis in normal and von Willebrand pigs: long-term prospective study and aortic transplantation study. Circ Res: 1982; 51 5 587 593 (Pubitemid 13236145)
38. Griggs TR, Reddick RL, Sultzer D, Brinkhous KM. Susceptibility to atherosclerosis in aortas and coronary arteries of swine with von Willebrand's disease. Am J Pathol: 1981; 102 2 137 145 (Pubitemid 12190453)
39. Badimon L, Steele P, Badimon JJ, Bowie EJ, Fuster V. Aortic atherosclerosis in pigs with heterozygous von Willebrand disease. Comparison with homozygous von Willebrand and normal pigs. Arteriosclerosis: 1985; 5 4 366 370 (Pubitemid 15068883)
40. Methia N, Andr P, Denis CV, Economopoulos M, Wagner DD. Localized reduction of atherosclerosis in von Willebrand factor-deficient mice. Blood: 2001; 98 5 1424 1428
41. Nichols TC, Bellinger DA, Tate DA., et al. von Willebrand factor and occlusive arterial thrombosis. A study in normal and von Willebrand's disease pigs with diet-induced hypercholesterolemia and atherosclerosis. Arteriosclerosis: 1990; 10 3 449 461 (Pubitemid 20178675)
42. Kleinschnitz C, De Meyer SF, Schwarz T., et al. Deficiency of von Willebrand factor protects mice from ischemic stroke. Blood: 2009; 113 15 3600 3603
43. De Meyer SF, Schwartz T, Deckmyn H., et al. Binding of von Willebrand factor to collagen and glycoprotein Ibalpha but not to glycoprotein IIb/IIIa, contributes to ischemic stroke in mice-brief report. Arterioscler Thromb Vasc Biol: 2010; 30 10 1949 1951
44. Silwer J, Cronberg S, Nilsson IM. Occurrence of arteriosclerosis in von Willebrand's disease. Acta Med Scand: 1966; 180 4 475 484
45. Kernoff LM, Rose AG, Hughes J, Jacobs P. Autopsy findings in an elderly man suffering from severe von Willebrand's disease. Thromb Haemost: 1981; 46 4 714 716 (Pubitemid 12198343)
46. Federici AB, Mannucci PM, Fogato E, Ghidoni P, Matturri L. Autopsy findings in three patients with von Willebrand disease type IIB and type III: presence of atherosclerotic lesions without occlusive arterial thrombi. Thromb Haemost: 1993; 70 5 758 761 (Pubitemid 23339448)
47. Bilora F, Dei Rossi C, Girolami B., et al. Do hemophilia A and von Willebrand disease protect against carotid atherosclerosis? A comparative study between coagulopathics and normal subjects by means of carotid echo-color Doppler scan. Clin Appl Thromb Hemost: 1999; 5 4 232 235 (Pubitemid 29529663)
48. Srmek A, Reiber JHC, Gerrits WBJ, Rosendaal FR. Decreased coagulability has no clinically relevant effect on atherogenesis: observations in individuals with a hereditary bleeding tendency. Circulation: 2001; 104 7 762 767 (Pubitemid 32762672)
49. Bilora F, Boccioletti V, Zanon E, Petrobelli F, Girolami A. Hemophilia A, von Willebrand disease, and atherosclerosis of abdominal aorta and leg arteries: factor VIII and von Willebrand factor defects appear to protect abdominal aorta and leg arteries from atherosclerosis. Clin Appl Thromb Hemost: 2001; 7 4 311 313 (Pubitemid 32988896)
50. Srmek A, Bucciarelli P, Federici AB., et al. Patients with type 3 severe von Willebrand disease are not protected against atherosclerosis: results from a multicenter study in 47 patients. Circulation: 2004; 109 6 740 744 (Pubitemid 38222893)
51. Bilora F, Zanon E, Casonato A., et al. Type IIb von Willebrand disease: role of qualitative defects in atherosclerosis and endothelial dysfunction. Clin Appl Thromb Hemost: 2007; 13 4 384 390 (Pubitemid 350114519)
52. Mannucci PM. Treatment of von Willebrand's disease. N Engl J Med: 2004; 351 7 683 694
53. Mannucci PM. Venous thromboembolism in von Willebrand disease. Thromb Haemost: 2002; 88 3 378 379 (Pubitemid 35021592)
54. Makris M, Colvin B, Gupta V, Shields ML, Smith MP. Venous thrombosis following the use of intermediate purity FVIII concentrate to treat patients with von Willebrand's disease. Thromb Haemost: 2002; 88 3 387 388 (Pubitemid 35021594)
55. Moss RA, Mena RR, Morin RJ. Atherosclerosis and a coronary artery bypass operation in a woman with von Willebrand disease. West J Med: 1980; 133 6 515 517
56. Goodnough LT, Saito H, Ratnoff OD. Thrombosis or myocardial infarction in congenital clotting factor abnormalities and chronic thrombocytopenias: a report of 21 patients and a review of 50 previously reported cases. Medicine (Baltimore): 1983; 62 4 248 255 (Pubitemid 13037004)
57. Dulhoste MN, Bonnet J, Vergnes C, Choussat A, Bricaud H. [von Willebrand's disease and coronary atherosclerosis. Apropos of 3 cases]. Arch Mal Coeur Vaiss: 1989; 82 11 1875 1878 (Pubitemid 19283334)
58. Slaughter TF, Mody EA, Oldham HN Jr., et al. Management of a patient with type IIC von Willebrand's disease during coronary artery bypass graft surgery. Anesthesiology: 1993; 78 1 195 197 (Pubitemid 23038995)
59. Wong CB, Schreiber TL. Acute myocardial infarction in a patient with von Willebrand disease. Cathet Cardiovasc Diagn: 1996; 38 3 287 288 (Pubitemid 26230944)
60. Fragasso G, Camba L, Pizzetti G, Pagnotta P, Chierchia SL. Successful thrombolysis for acute myocardial infarction in Type I von Willebrand's disease (vWD). Am J Hematol: 1998; 57 2 180 (Pubitemid 28096544)
61. James PR, de Belder AJ, Kenny MW. Successful percutaneous transluminal coronary angioplasty for acute myocardial infarction in von Willebrand's disease. Haemophilia: 2002; 8 6 826 827 (Pubitemid 35446640)
62. Arjomand H, Aquilina P, McCormick D. Acute myocardial infarction in a patient with von Willebrand disease: pathogenetic dilemmas and therapeutic challenges. J Invasive Cardiol: 2002; 14 10 615 618 (Pubitemid 35178259)
63. Franchini M, Veneri D. Are only haemophiliacs protected against ischemic heart disease? Thromb Haemost: 2004; 92 6 1455 1456
64. Grainge C, Nokes T. Cerebral arterial thrombosis in a young woman following vasopressin for von Willebrand's disease. Thromb Haemost: 2005; 93 2 380 (Pubitemid 40253747)
65. Macdonald J, Srinivasan M, More R. Percutaneous coronary intervention in a patient with von Willebrand's disease presenting with an acute coronary syndrome. J Invasive Cardiol: 2006; 18 4 174 177 (Pubitemid 44576093)
66. Gerling V, Lahpor JR, Buhre W. Peri-operative management of an adult patient with type 2N von Willebrand's disease scheduled for coronary artery bypass graft. Anaesthesia: 2007; 62 4 405 408 (Pubitemid 46487254)
67. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ: 2002; 324 7329 71 86
68. Patrono C, Baigent C, Hirsh J, Roth G.; American College of Chest Physicians. Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest: 2008; 133 6 Suppl 199S 233S (Pubitemid 351894914)
69. Harrington RA, Becker RC, Cannon CP., et al. American College of Chest Physicians. Antithrombotic therapy for Non-ST-Segment Elevation Acute coronary syndromes. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest: 2008; 133 6 Suppl 670S 707S (Pubitemid 351892975)
70. Goodman SG, Menon V, Cannon CP., et al. American College of Chest Physicians. Acute ST-Segment Elevation Myocardial Infarction. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest: 2008; 133 6 Suppl 708S 775S (Pubitemid 351892976)
71. Moscucci M, Fox KA, Cannon CP., et al. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J: 2003; 24 20 1815 1823 (Pubitemid 37280247)
72. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med: 2001; 344 17 1286 1292 (Pubitemid 32372963)
73. Merlini PA, Rossi M, Menozzi A., et al. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting. Circulation: 2004; 109 18 2203 2206 (Pubitemid 38625397)
74. Ky B, Kasner M, Carver JR. von Willebrand disease and coronary artery disease: a contemporary review. J Invasive Cardiol: 2006; 18 4 178 182 (Pubitemid 44576094)
75. Greenland P, Alpert JS, Beller GA., et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation: 2010; 122 25 2748 2764
76. D'Agostino RB Sr, Vasan RS, Pencina MJ., et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation: 2008; 117 6 743 753 (Pubitemid 351640675)
77. Conroy RM, Pyörälä K, Fitzgerald AP., et al. SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J: 2003; 24 11 987 1003 (Pubitemid 36712275)
78. Biere-Rafi S, Baarslag MA, Peters M., et al. Cardiovascular risk assessment in haemophilia patients. Thromb Haemost: 2011; 105 2 274 278
79. Shaw SM, Fildes JE, Yonan N, Williams SG. Pleiotropic effects and cholesterol-lowering therapy. Cardiology: 2009; 112 1 4 12
80. Yarnell JW, Sweetnam PM, Rumley A, Lowe GD. Lifestyle and hemostatic risk factors for ischemic heart disease: the Caerphilly Study. Arterioscler Thromb Vasc Biol: 2000; 20 1 271 279 (Pubitemid 30048375)
81. Barbui T, Rodeghiero F, Dini E. The aspirin tolerance test in von Willebrand's disease. Thromb Haemost: 1977; 38 2 510 513 (Pubitemid 8194147)
82. Miesbach W, Berntorp E. When von Willebrand disease comes into age - a matter of change? Eur J Haematol: 2011; 86 6 496 501
83. Federici AB. Prophylaxis of bleeding episodes in patients with von Willebrand's disease. Blood Transfus: 2008; 6 Suppl 2 s26 s32
84. Savonitto S, Ardissino D, Granger CB., et al. Prognostic value of the admission electrocardiogram in acute coronary syndromes. JAMA: 1999; 281 8 707 713 (Pubitemid 29113451)
85. Kinnaird T, Anderson R, Hill J, Thomas M. Bleeding during percutaneous intervention: tailoring the approach to minimise risk. Heart: 2009; 95 1 15 19
86. Cantor WJ, Puley G, Natarajan MK., et al. Radial versus femoral access for emergent percutaneous coronary intervention with adjunct glycoprotein IIb/IIIa inhibition in acute myocardial infarctionthe RADIAL-AMI pilot randomized trial. Am Heart J: 2005; 150 3 543 549 (Pubitemid 41317627)
87. Koreny M, Riedmüller E, Nikfardjam M, Siostrzonek P, Müllner M. Arterial puncture closing devices compared with standard manual compression after cardiac catheterization: systematic review and meta-analysis. JAMA: 2004; 291 3 350 357 (Pubitemid 38101608)
88. Mannucci PM, Franchini M, Castaman G, Federici AB.; Italian Association of Hemophilia Centers. Evidence-based recommendations on the treatment of von Willebrand disease in Italy. Blood Transfus: 2009; 7 2 117 126
89. Budde U, Metzner HJ, Müller HG. Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease. Semin Thromb Hemost: 2006; 32 6 626 635 (Pubitemid 44453024)
90. Antman EM, Cohen M, Radley D., et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. Circulation: 1999; 100 15 1602 1608 (Pubitemid 29477268)
91. Ferguson JJ, Califf RM, Antman EM., et al. SYNERGY Trial Investigators. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA: 2004; 292 1 45 54
92. Karthikeyan G, Mehta SR, Eikelboom JW. Fondaparinux in the treatment of acute coronary syndromes: evidence from OASIS 5 and 6. Expert Rev Cardiovasc Ther: 2009; 7 3 241 249
93. Maroo A, Lincoff AM. Bivalirudin in PCI: an overview of the REPLACE-2 trial. Semin Thromb Hemost: 2004; 30 3 329 336 (Pubitemid 39037626)
94. Harker LA, Boissel JP, Pilgrim AJ, Gent M. Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events. Drug Saf: 1999; 21 4 325 335
95. Iakovou I, Schmidt T, Bonizzoni E., et al. Incidence, prediction and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA: 2005; 4;293 17 2126 2130 (Pubitemid 40617065)
96. Banerjee S, Varghese C, Samuel J., et al. Comparison of the impact of short (<1 year) and long-term (> or = 1 year) clopidogrel use following percutaneous coronary intervention on mortality. Am J Cardiol: 2008; 102 9 1159 1162
97. Kwa AT, Rogers JH. Current update on glycoprotein IIb-IIIa and direct thrombin inhibition in percutaneous coronary intervention for non-ST elevation acute coronary syndromes: balancing bleeding risk and antiplatelet efficacy. J Interv Cardiol: 2008; 21 2 107 117 (Pubitemid 351492480)
98. Franchini M, Mannucci PM. New antiplatelet agents: why they are needed. Eur J Intern Med: 2009; 20 8 733 738
99. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation: 1994; 90 1 583 612
100. Italian Society of Invasive Cardiology. Available at: www.gise.it. Accessed on August 19, 2011
101. Tosetto A, Castaman G, Plug I, Rodeghiero F, Eikenboom J. Prospective evaluation of the clinical utility of quantitative bleeding severity assessment in patients referred for hemostatic evaluation. J Thromb Haemost: 2011; 9 6 1143 1148